Obesity is a chronic, progressive, relapsing disease — not a personal failure. This book examines tirzepatide and what a new generation of metabolic medicines means for treatment, prevention, and public health.
Tirzepatide: A New Perspective on Obesity, Metabolism, and the Future of Treatment
Obesity is not simply a number on a scale. Modern medicine treats it as a chronic, progressive, relapsing disease involving appetite, metabolism, and brain function — and a new generation of metabolic medicines has changed what treatment can offer. Prof. Seyed-Moayed Alavian examines tirzepatide, the science behind it, and what it means for individuals and for public health.
Publisher
Publication date
May 29, 2026
Print length
300 pages
Language
English
Format
Kindle edition
Subject
Obesity medicine and metabolic health
Audience
Patients, clinicians, and health policymakers
Get the book
Published by Brieflands and available worldwide as a Kindle edition on Amazon. For institutional orders, bulk copies, or translation rights, contact the publisher directly.
Obesity — a matter beyond weight
At first glance obesity may look like an increase in body weight or BMI. In reality it is among the most complex health problems of the modern era, with roots that extend well beyond overeating or inactivity into biological, psychological, social, and economic territory.
The rising global prevalence of obesity over recent decades makes clear that it is not simply the product of individual choices. Lifestyle change, unhealthy food environments, chronic stress, sleep disorders, genetic and hormonal factors, and health policy itself all contribute to how obesity develops and persists. An oversimplified view does not just fail to help treatment — it produces social stigma, patient blame, and delayed intervention.
From the perspective of modern medicine, obesity is a chronic, progressive, and relapsing disease associated with dysregulation of appetite, metabolism, and brain function. It is directly linked to increased risk of type 2 diabetes, cardiovascular disease, fatty liver, certain cancers, and mental health disorders, and it materially affects quality of life.
Only with such a perspective can an effective treatment path be designed, where obesity is not viewed as a personal failure, but as a manageable challenge at both the individual and societal levels.Prof. Seyed-Moayed Alavian — from the opening chapter
What the book covers
A scientific, humane, and sustainable approach to treatment.
Obesity as a disease
Why modern medicine classifies obesity as chronic and relapsing, and what follows from that framing.
The metabolic mechanism
How appetite, metabolism, and brain signalling interact — the biology these medicines act on.
Tirzepatide in context
Where this treatment sits among the options available, and what the clinical evidence describes.
Associated conditions
The links to type 2 diabetes, cardiovascular disease, fatty liver, cancer risk, and mental health.
Beyond blame
Why stigma delays effective care, and what a non-judgemental clinical approach looks like.
A societal view
Food environments, health policy, and treatment access as part of the same problem.
Important. Tirzepatide is a prescription medicine. This book is educational and does not recommend, prescribe, or provide dosing guidance for any treatment. Decisions about starting, changing, or stopping any obesity or diabetes medication must be made with a qualified clinician who can assess your history, other medications, and possible adverse effects. Never obtain prescription medicines from unregulated sources.